Ultragenyx Pharmaceutical Inc. (RARE) Expected to Announce Quarterly Sales of $410,000.00

Equities research analysts predict that Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) will report sales of $410,000.00 for the current quarter, according to Zacks. Three analysts have made estimates for Ultragenyx Pharmaceutical’s earnings, with the highest sales estimate coming in at $1.00 million and the lowest estimate coming in at $100,000.00. Ultragenyx Pharmaceutical reported sales of $10,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 4,000%. The firm is expected to announce its next earnings report on Thursday, February 15th.

On average, analysts expect that Ultragenyx Pharmaceutical will report full year sales of $410,000.00 for the current year, with estimates ranging from $190,000.00 to $2.36 million. For the next financial year, analysts expect that the business will post sales of $37.48 million per share, with estimates ranging from $2.60 million to $226.60 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) EPS for the quarter, meeting analysts’ consensus estimates of ($1.87). The business had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.02 million. Ultragenyx Pharmaceutical’s quarterly revenue was up 81.8% on a year-over-year basis. During the same period in the previous year, the company posted ($1.64) earnings per share.

RARE has been the subject of several analyst reports. Barclays increased their price target on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the stock an “equal weight” rating in a report on Tuesday, December 5th. Canaccord Genuity set a $80.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Tuesday, December 5th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a “sell” rating to a “hold” rating in a report on Wednesday, November 8th. J P Morgan Chase & Co set a $76.00 price target on shares of Ultragenyx Pharmaceutical and gave the stock a “buy” rating in a report on Wednesday, August 23rd. Finally, Morgan Stanley reissued an “equal weight” rating and set a $69.00 price target (down from $80.00) on shares of Ultragenyx Pharmaceutical in a report on Wednesday, August 23rd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company’s stock. Ultragenyx Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $72.40.

Ultragenyx Pharmaceutical (NASDAQ RARE) opened at $44.68 on Friday. Ultragenyx Pharmaceutical has a 1-year low of $43.38 and a 1-year high of $91.35.

Institutional investors and hedge funds have recently modified their holdings of the business. Sei Investments Co. acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $125,000. SG Americas Securities LLC acquired a new position in Ultragenyx Pharmaceutical during the third quarter worth about $156,000. Tocqueville Asset Management L.P. grew its position in Ultragenyx Pharmaceutical by 8.0% during the second quarter. Tocqueville Asset Management L.P. now owns 3,375 shares of the biopharmaceutical company’s stock worth $210,000 after buying an additional 250 shares during the period. Pacer Advisors Inc. grew its position in Ultragenyx Pharmaceutical by 12.0% during the second quarter. Pacer Advisors Inc. now owns 3,402 shares of the biopharmaceutical company’s stock worth $211,000 after buying an additional 365 shares during the period. Finally, Kazazian Asset Management LLC acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth about $213,000. Institutional investors own 94.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This article was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this article on another website, it was illegally copied and republished in violation of U.S. and international copyright and trademark law. The original version of this article can be accessed at https://www.americanbankingnews.com/2017/12/16/ultragenyx-pharmaceutical-inc-rare-expected-to-announce-quarterly-sales-of-410000-00.html.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply